

EASY ACCESS TO ALIPHATIC SULFONAMIDES USING SULFAMOYL CHLORIDES UNDER VISIBLE LIGHT ACTIVATION

3

AUTHORS & AFFILIATIONS:

5Sandrine M. Hell¹, Claudio F. Meyer^{1,2}, Andrés A. Trabanco² and Véronique Gouverneur¹

7¹University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford, OX1 3TA,
8United Kingdom

9²Discovery Chemistry, Janssen Research and Development, Jarama 75A, Toledo, E-45007, Spain

10

Corresponding Author:

12Véronique Gouverneur at veronique.gouverneur@chem.ox.ac.uk

13

Email Addresses of Co-Authors:

15Sandrine M. Hell (sandrine.hell@chem.ox.ac.uk)

16Claudio F. Meyer (claudio.meyer@chem.ox.ac.uk)

17Andrés A. Trabanco (atrabanc@its.jnj.com)

18

KEYWORDS:

20Blue-light activation, radical, H-atom donor, late-stage functionalization, commercial reagents,
21hydrofunctionalization, electron-deficient alkenes.

22

SUMMARY:

24Presented here is a protocol for the easy synthesis of aliphatic sulfonamides using sulfamoyl
25chlorides, (TMS)₃SiH and Eosin Y under blue-light irradiation.

26

ABSTRACT:

28Sulfonamides are prevalent motifs in marketed drugs and natural products. Their synthesis
29represents a great interest to the pharmaceutical industry, due to their unique biological
30properties. Recently, several methods for the synthesis of aryl sulfonamides have been
31developed, but little effort has focused on developing one-step methodologies to access
32sulfonamides flanked by two alkyl groups. This protocol describes a practical and facile method
33for the net hydrosulfamoylation of electron-deficient alkenes using sulfamoyl chlorides as
34radical precursors under blue-light activation. This practical and cost-effective methodology is
35performed in the presence of the metal-free photocatalyst Eosin Y and uses light as a clean and
36traceless energy source. The procedure is scalable, displays a broad functional group tolerance,
37and can be applied for late-stage functionalization. All reagents used in this protocol are
38commercially available. Simple reaction set-up, the absence of work-up and easy purification,
39demonstrate the convenience of this protocol. The reaction is best applied to electron-deficient
40alkenes.

41

INTRODUCTION:

43Over the recent decades, sulfonamides featured in a broad range of biologically active
44molecules and are common motifs in pharmaceuticals and agrochemicals^{1,2}. Initially employed
45for antibacterial purposes^{3,4}, the application of this motif in drug discovery has been extended

46to numerous diseases including cancer, CNS disorders, diabetes, dementia and HIV⁵⁻¹¹.
47Sulfonamides stand out as metabolically stable bioisosteres of carboxylic acids and
48carboxamides, with the N-H pKa being tunable by varying substitution patterns¹²⁻¹⁵.

49

50Traditionally, sulfonamides are synthesized by substitution of a sulfonyl chloride with an
51amine^{16,17}. The synthesis of sulfonyl chlorides often relies on a multi-step procedure employing
52harsh conditions, such as strong oxidants. Whilst milder one-step protocols for the installation
53of sulfonyl chloride intermediates have been developed^{18,19}, the design of a single-step
54transformation to access sulphonamides is highly desirable.

55

56In the last decades, powerful strategies have been developed for the synthesis of (hetero)aryl
57sulfonamides, using transition metals, photoredox catalysis or organic catalysts²⁰⁻³⁴.
58Nevertheless, the one-step synthesis of aliphatic analogues remains underexplored³⁵⁻⁴⁰. A
59notable exception is the electrochemical oxidative coupling of amines and thiols, reported by
60Noël and co-workers⁴¹. We were interested in a complementary late-stage functionalization
61strategy, allowing the direct attachment of commercially available sulfamoyl chlorides onto
62inexpensive olefins to afford products of net hydrosulfamoylation under visible light activation.
63Specifically, this process requires an in situ generated sulfamoyl radical, and a suitable
64hydrogen atom donor.

65

66Preliminary studies indicated that the direct single electron reduction of dimethylsulfamoyl
67chloride ($E_{\text{red}} = -1.59$ V versus saturated calomel electrode (SCE) in MeCN)⁴² is more challenging
68than for methanesulfonyl chloride ($E_{\text{red}} = -1.30$ V versus SCE in MeCN)⁴³, an observation
69encouraging the identification of an alternative mode of activation to generate sulfamoyl
70radicals. Inspired by Chatgililoglu's work in 1988⁴⁴, we believed that tris(trimethylsilyl)silane
71can act both as a silyl radical source capable of activating sulfamoyl chlorides, and as the
72hydrogen atom donor. Blue light irradiation is essential for this reaction to proceed, while Eosin
73Y is beneficial but not essential.

74

75This practical and cost-effective one-step method tolerates numerous functional groups,
76thereby allowing access to a broad range of novel alkylsulfonamides including complex
77sulfonamide-containing cyclobutyl-spirooxindoles that are all valuable building blocks for drug
78discovery. As part of the challenges faced by industries aiming at avoiding operationally
79complex, over-engineered, and costly processes, this transformation is not sensitive to oxygen
80or moisture, uses a metal free photocatalyst, and is operationally simple. Furthermore, the use
81of blue light as an initiator for this chemical transformation makes this protocol green and
82sustainable.

83

84**PROTOCOL:**

85

86CAUTION: All chemicals used in this protocol must be handled with care. Please carefully read
87the material safety data sheets (MSDS) of solvents and reagents used in this protocol.
88(TMS)₃SiH, dimethylsulfamoyl chloride, MeCN, EtOAc and silica have been shown to be toxic,
89corrosive, irritant, cancerogenic and flammable. Standard lab safety measures are relevant for

90the handling of those chemicals. All manipulations must be performed in a ventilated
91laboratory fume hood and the use of appropriate personal protective equipment (PPE),
92including lab coat, safety glasses, and nitrile gloves is compulsory.

93

94**1. Hydrosulfamoylation of electron-deficient alkenes**

95

961.1. Add a magnetic stir bar to a 7 mL vial.

97

981.2. Weigh out 73.5 mg of *N*-phenylacrylamide (0.50 mmol, 1.0 equiv) and 1.7 mg of
99photocatalyst Eosin Y (0.0025 mmol, 0.5 mol%) and add both to the same vial.

100

1011.3. Sequentially add 3.0 mL of MeCN, 309 μ L of (TMS)₃SiH (1.0 mmol, 2.0 equiv) and 1.25 mmol
102of sulfamoyl chloride (2.5 equiv) with a syringe. Cap the vial with a screw cap.

103

1041.4. Place the vial in the photobox equipped with an 18 W blue LED lamp (λ = 450 nm) and a
105fan.

106

1071.5. Stir the emulsion vigorously at 1,000 rpm for 4 h.

108

109**2. Monitoring of the starting material conversion by thin-layer chromatography (TLC)**

110

1112.1. Dissolve 1 mg of *N*-phenylacrylamide in 1 mL of Dichloromethane (DCM). Sample this
112solution on the TLC plate (left and middle spot).

113

1142.2. Sample a 50 μ L aliquot of the reaction mixture and transfer it to a 1.5 mL vial containing 50
115 μ L of DCM. Sample this solution on the TLC plate (middle and right spot).

116

1172.3. Add a solvent mixture of pentane and ethyl acetate (eluent: 80:20 pentane/ethyl acetate)
118to a TLC chamber.

119

1202.4. Run the TLC plate in the chamber until the solvent front is at 0.5 cm distance of the top of
121the plate.

122

1232.5. Remove the plate from the chamber, dry it under air and expose the plate to UV light (λ =
124254 nm) under a lamp (*R_f* values: Starting material = 0.4; Product = 0.2).

125

126**3. Workup and purification**

127

1283.1. Transfer the reaction mixture to a 25 mL round-bottom flask and concentrate the mixture
129under reduced pressure using a rotary evaporator (150 rpm; until 20 mbar) equipped with a
130water bath, heated to 40 °C to obtain a crude oil.

131

1323.2. Condition a silica column (pore size 60 Å, 230 – 400 mesh particle size, 12 g) by passing 60
133mL of pentane through the column via a syringe.

134

1353.3. Dilute the crude oil in 2 mL of DCM and transfer the solution onto the column.

136

1373.4. Run a gradient elution on the automated column (EtOAc in pentane 0/100 to 100/0 over 20 138min) and monitor by UV-VIS (254 nm) to elute the compounds.

139

1403.5. Collect the fractions in test tubes and monitor the collected fractions by TLC (see section 2).

141

1423.6. Sample aliquots of the collected fractions on a TLC plate.

143

1443.7. Run the TLC plate in the chamber until the solvent front has almost reached the top of the 145plate and compare the *R_f* values (see section 2.5).

146

1473.8. Collect the desired fractions as determined by TLC analysis and concentrate the solution 148under reduced pressure on a rotary evaporator (150 rpm; until 20 mbar) equipped with a water 149bath heated to 40 °C.

150

1513.9. Dissolve 5 mg of the product in 0.6 mL CDCl₃ and add this solution to a NMR (Nuclear 152Magnetic Resonance Spectroscopy) tube.

153

1543.10. Run a ¹H NMR and a ¹³C NMR in CDCl₃ and compare the spectra with the information listed 155below.

156

157**REPRESENTATIVE RESULTS:**

158The sequence produced the desired hydrosulfamoylated product with 83% yield (106 mg, 0.41 159mmol) as an off-white solid. The structure and purity can be assessed by ¹H and ¹³C NMR 160spectra (**Figure 1**, **Figure 2**). More specifically, in the ¹H and ¹³C NMR, disappearance of two 161characteristic alkene peaks and appearance of two aliphatic peaks, are characteristic for the 162addition of dimethyl sulfamoyl chloride to the alkene. High-resolution mass spectrometry 163(HRMS) of the product also confirmed the formation of the desired product.

164

165**3-(*N,N*-dimethylsulfamoyl)-*N*-phenylpropanamide**

166¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, 1H), 7.51 (d, *J* = 7.6 Hz, 2H), 7.29 (dd, *J* = 7.9 Hz, 2H), 7.09 167(dd, *J* = 7.4 Hz, 1H), 3.35 (t, *J* = 7.5 Hz, 2H), 2.91 (t, *J* = 7.5 Hz, 2H), 2.87 (s, 6H); ¹³C NMR (101 168MHz, CDCl₃) δ 167.9, 137.9, 129.1, 124.6, 120.0, 43.5, 37.5, 30.5; **HRMS** (ESI-TOF) calculated for 169C₁₁H₁₅O₃N₂³²S [M-H]⁺: 255.0809; found 255.0806; **IR** (neat) 1681, 1619, 1551, 1491, 1443, 1336, 1701314, 1258, 1186, 1147, 952, 760, 742, 684; **m.p.**: 120–122 °C.

171

172A wide range of novel aliphatic sulfonamides can be prepared using this methodology in good 173to high yields.⁴² Each compound has been fully characterized by ¹H, ¹³C NMR, as well as HRMS, 174IR and melting point.⁴² Note that vigorous stirring is required, due to the use of (TMS)₃SiH, 175which is not miscible in MeCN. Depending on the substrate, the completion of the reaction 176could be monitored visually as at this point, the mixture becomes homogenous. A colour

change was observed upon addition of dimethylsulfamoyl chloride. No degradation of the product was observed when the reaction time was extended to 72 h.

FIGURE LEGENDS:

Figure 1: ^1H NMR spectra of 1a and 3a (CDCl_3 , 400 MHz). This figure has been modified from Gouverneur and co-workers⁴².

Figure 2: ^{13}C NMR spectra of 1a and 3a (CDCl_3 , 101 MHz). This figure has been modified from Gouverneur and co-workers⁴².

Figure 3: Suggested mechanism for the hydrosulfamoylation of alkenes. This figure has been modified from Gouverneur and co-workers⁴².

Figure 4: Substrate scope of sulfamoyl chlorides and alkenes. Reaction conditions: alkene **1** (0.5 mmol), sulfamoyl chloride **2** (1.25 mmol), $(\text{TMS})_3\text{SiH}$ (1.0 mmol), Eosin Y (0.5 mol%), MeCN (3.0 mL), blue LED irradiation ($\lambda_{\text{max}} = 470 \text{ nm}$), room temperature. [a] 16 h reaction time. [b] Scale-up experiment performed on 30.8 mmol (5.0 g) of benzyl acrylate. [c] The diastereomers were separated by silica flash column chromatography. [d] The minor isomer was not isolated. [e] Only traces of the hydrosulfamoylated product was observed. This figure has been modified from Gouverneur and co-workers⁴².

DISCUSSION:

This operationally simple protocol uses commercially available substrates. Nitrogen atmosphere as well as strict water-free conditions are not required for the reaction to proceed in high yields, demonstrating the ease of this protocol. These reactions are often complete within 4 h at room temperature, although some less reactive sulfamoyl chlorides required additional time.

The absence of work-up and the ease of the purification step by silica column chromatography, make this protocol operationally and economically attractive. Interestingly, a fluctuation of the temperature (depending on the distance between the vial and the lamp) did not impact the outcome of the reaction. We noticed that a high purity of the sulfamoyl chlorides was crucial for this transformation to proceed in good yield.

Aiming at broadening the scope, the reactivity of the sulfamoyl radical was investigated towards a range of alkenes of different electronic profiles. As shown previously, the sulfamoyl radical can be added efficiently to electron-deficient alkenes; nevertheless, no conversion was observed with styrenes and unactivated alkenes. Current investigations for the compatibility of these substrates under our reaction conditions is ongoing. Furthermore, sulfonyl chlorides have been shown to be reactive under similar reaction conditions.⁴⁵

A plausible mechanism of the hydrosulfamoylation of electron-deficient alkenes is depicted in **Figure 3**. Upon irradiation with light, the generated excited triplet state Eosin Y* [$E_{1/2}^{\text{red}}(\text{PC}^*/\text{PC}^{\cdot-}) = +0.83 \text{ V}$ versus saturated calomel electrode (SCE)] should readily oxidize tris(trimethylsilyl)silane (TTMSS) [$E^{\text{ox}}(\text{TTMSS}/\text{TTMSS}^{\cdot+}) = +0.73 \text{ V}$ versus SCE] via single-electron

transfer (SET). Upon loss of a proton, silyl radical **A** is generated, which subsequently abstracts a chlorine-atom from the sulfamoyl chloride to generate sulfamoyl radical **B**. The latter radical **B** undergoes regioselective Giese addition to the alkene, whereby the C-centered radical **C** is formed. The desired hydrosulfamoylated product is finally obtained upon single-electron reduction and protonation (Path A). In this event, the photocatalyst returns to its native oxidation state. A chain propagation reaction mechanism, involving a direct H-atom abstraction from TTMSS is also viable (Path B).

229

This protocol tolerates a wide range of functional groups, such as esters, amides, carboxylic acids, amines, ethers, halides, nitro and nitriles (**Figure 4: 3a–3ah**). The successful introduction of primary, secondary as well as tertiary sulfonamides allowed access to a broad range of novel alkylsulfonamides (**3a–3ao**). Linear terminal alkenes (**3p–3w**), gem-disubstituted alkenes (**3x,y**), and a representative electron-deficient alkyne (**3ab**) are all suitable substrates. Cyclobutenes respond well to hydrosulfamoylation generating highly desirable 1,2-disubstituted sulfonamide-containing cyclobutanes (**3z,3aa**) or cyclobutyl-spirooxindoles (**3af–3ah**), all valuable building blocks for drug discovery. The diastereoisomers formed, are easily separable by flash column chromatography. Late-stage functionalization of biologically active molecules was also successful (**3ad, 3ae**). The scalability of this transformation was demonstrated, providing a short and safe synthetic route to access **3w**. We noted competitive desulfonylation with *N*-benzylmaleimide (**3ac**).

242

As an economic and efficient protocol, this protocol could have practical significance for the introduction of aliphatic sulfonamides in complex natural products and biologically active molecules, in both academic laboratory and industry laboratories.

246

247ACKNOWLEDGMENTS:

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 721902.

250

251DISCLOSURES:

The authors have nothing to disclose.

253

254REFERENCES:

1. Feng, M., Tang, B., Liang, S. H., Jiang, X. Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry. *Current Topics in Medicinal Chemistry* **16**, 1200–1216 (2016).

2. Drews, J. Drug discovery: a historical perspective. *Science*. **287**, 1960–1964 (2000).

3. Wainwright, M., Kristiansen, J. E. On the 75th anniversary of Prontosil. *Dyes Pigments*. **88**, 260231–234 (2011).

4. Zaffiri, L., Gardner, J., Toledo-Pereyra, L. H. History of antibiotics. From Salvarsan to Cephalosporins. *Journal of Investigative Surgery* **25**, 67–77 (2012).

5. Casini, A., Scozzafava, A., Mastrolorenzo, A., Supuran, C. T. Sulfonamides and Sulfonylated Derivatives as Anticancer Agents. *Current Cancer Drug Targets* **2**, 55–75 (2002).

2656. Shah, S. A., Rivera, G., Ashfaq, M. Recent Advances in Medicinal Chemistry of Sulfonamides. 266Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents. *Mini-Reviews in* 267*Medicinal Chemistry*. **13**, 70–86 (2013).

2687. Smith, B. R., Eastman, C. M., Njardarson, J. T. Beyond C, H, O, and N! Analysis of the 269Elemental Composition of U.S. FDA Approved Drug Architectures. *Journal of Medicinal* 270*Chemistry* **57**, 9764–9773 (2014).

2718. Ilardi, E. A., Vitaku, E., Njardarson, J. T. Data-Mining for Sulfur and Fluorine: An Evaluation of 272Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery. *Journal of Medicinal* 273*Chemistry* **57**, 2832–2842 (2014)

2749. Bag, S., Tulsan, R., Sood, A., Cho, H., Redjeb, H., Zhou, W., LeVine III, H., Török, B., Török, M. 275Sulfonamides as multifunctional agents for Alzheimer's disease. *Bioorganic & Medicinal* 276*Chemistry Letters* **25**, 626–630 (2015).

27710. Gao, H.-D., Liu, P., Yang, Y., Gao, F. Sulfonamide-1,3,5-triazine–thiazoles: discovery of a 278novel class of antidiabetic agents *via* inhibition of DPP-4. *RSC Advances* **6**, 83438–83447 (2016).

27911. Apaydın, S., Török, M. Sulfonamide derivatives as multi-target agents for complex diseases. 280*Bioorganic & Medicinal Chemistry Letters* **29**, 2042–2050 (2019).

28112. Pinter, T., Jana, S., Courtemanche, R. J. M., Hof, F. Recognition Properties of Carboxylic Acid 282Bioisosteres: Anion Binding by Tetrazoles, Aryl Sulfonamides, and Acyl Sulfonamides on a 283Calix[4]arene Scaffold. *The Journal of Organic Chemistry* **76**, 3733–3741 (2011).

28413. Ballatore, C., Huryn, D. M., Smith III, A. B. Carboxylic Acid (Bio)Isosteres in Drug Design. 285*ChemMedChem* **8**, 385–395 (2013).

28614. Lassalas, P., Gay, B., Lasfargeas, C., James, M. J., Tran, V., Vijayendran, K. G., Brunden, K. R., 287Kozlowski, M. C., Thomas, C. J., Smith III, A. B., Huryn, D. M., Ballatore, C. Structure Property 288Relationships of Carboxylic Acid Isosteres. *Journal of Medicinal Chemistry* **59**, 3183–3203 289(2016).

29015. Şanlı, N.; Şanlı, S.; Özkan, G.; Denizlic, A. Determination of pK_a values of some sulfonamides 291by LC and LC-PDA methods in acetonitrile-water binary mixtures. *Journal of the Brazilian* 292*Chemical Society* **21**, 1952–1960 (2010).

29316. Bahrami, K., Khodaei, M. M., Soheilzad, M. Direct Conversion of Thiols to Sulfonyl Chlorides 294and Sulfonamides. *The Journal of Organic Chemistry* **74**, 9287–9291 (2009).

29517. Veisi, H., Ghorbani-Vaghei, R., Hemmati, S., Mahmoodi, J. Convenient One-Pot Synthesis of 296Sulfonamides and Sulfonyl Azides from Thiols Using *N*-Chlorosuccinimide. *Synlett* **16**, 2315– 2972320 (2011).

29818. Rawner, T., Knorn, M., Lutsker, E., Hossain, A., Reiser O. Synthesis of Trifluoromethylated 299Sultones from Alkenols Using a Copper Photoredox Catalyst. *The Journal of Organic Chemistry* 300**81**, 7139–7147 (2016).

30119. Bagal, D. B., Kachkovskyi, G., Knorn, M., Rawner, T., Bhanage, B. M., Reiser, O. 302Trifluoromethylchlorosulfonylation of Alkenes:Evidence for an Inner-Sphere Mechanism by a 303Copper Phenanthroline Photoredox Catalyst. *Angewandte Chemie International Edition* **54**, 3046999–7002 (2015).

30520. Yin, J., Buchwald, S. L. Palladium-Catalyzed Intermolecular Coupling of Aryl Halides and 306Amides. *Organic Letters* **2**, 1101–1104 (2000).

30721. Burton, G., Cao, P., Li, G., Rivero, R. Palladium-Catalyzed Intermolecular Coupling of Aryl 308Chlorides and Sulfonamides under Microwave Irradiation. *Organic Letters* **5**, 4373–4376 (2003);

30922. Shaabani, A., Soleimani, E., Rezayan, A. H. A novel approach for the synthesis of alkyl and
 310aryl sulfonamides. *Tetrahedron Letters* **48**, 2185–2188 (2007).

31123. Baffoe, J., Hoe, M. Y., Touré, B. B. Copper-Mediated *N*-Heteroarylation of Primary
 312Sulfonamides: Synthesis of Mono-*N*-heteroaryl Sulfonamides. *Organic Letters* **12**, 1532–1535
 313(2010).

31424. DeBergh, J. R., Niljianskul, N., Buchwald, S. L. Synthesis of Aryl Sulfonamides via Palladium-
 315Catalyzed Chlorosulfonylation of Arylboronic Acids. *Journal of the American Chemical Society*
 316**135**, 10638–10641 (2013).

31725. Yang, B., Lian, C., Yue, G., Liu, D., Wei, L., Ding, Y., Zheng, X., Lu, K., Qiu, D., Zhao, X.
 318Synthesis of *N*-arylsulfonamides through a Pd-catalyzed reduction coupling reaction of
 319nitroarenes with sodium arylsulfonates. *Organic & Biomolecular Chemistry* **16**, 8150–8154
 320(2018).

32126. Chen, Y., Murray, P. R. D., Davies, A. T., Willis, M. C. Direct Copper-Catalyzed Three-
 322Component Synthesis of Sulfonamides. *Journal of the American Chemical Society* **140**, 8781–
 3238787 (2018).

32427. Kim, T., McCarver, S. J., Lee C., MacMillan, D. W. C. Sulfonamidation of Aryl and Heteroaryl
 325Halides through Photosensitized Nickel Catalysis. *Angewandte Chemie International Edition* **57**,
 3263488–3492 (2018).

32728. Chan, W. Y., Berthelette, C. A mild, efficient method for the synthesis of aromatic and
 328aliphatic sulfonamides. *Tetrahedron Letters* **43**, 4537–4540 (2002).

32929. Burrows, J. N., Tucker, H. 1-Sulphonyl piperidine derivatives. WO 2004/024698A1 (2004);

33030. Burns, D. M., Yao, W., He, C. Hydroxamic acid derivatives as metalloprotease inhibitors. WO
 3312005/117882A2 (2005).

33231. Cumming, J. N., Gilbert, E. J., Stamford, A. W. C5-c6 oxacyclic-fused thiadiazine dioxide
 333compounds as BACE inhibitors, compositions, and their use. WO 2012/138734A1, (2012).

33432. Joyard, Y., Papamicaël, C., Bohn, P., Bischoff, L. Synthesis of Sulfonic Acid Derivatives by
 335Oxidative Deprotection of Thiols Using *tert*-Butyl Hypochlorite *Organic Letters* **15**, 2294–2297
 336(2013).

33733. Shavnya, A., Coffey, S. B., Hesp, K. D., Ross, S. C., Tsai, A. S. Reaction of Alkyl Halides with
 338Rongalite: One-Pot and Telescoped Syntheses of Aliphatic Sulfonamides, Sulfonyl Fluorides, and
 339Unsymmetrical Sulfones. *Organic Letters* **18**, 5848–5851 (2016).

34034. Wang, M., Fan Q., Jiang X. Metal-free construction of primary sulfonamides through three
 341diverse salts. *Green Chemistry* **20**, 5469–5473 (2018).

34235. Wallentin, C.-J., Nguyen, J. D., Finkbeiner, P., Stephenson, C. R. J. Visible Light-Mediated
 343Atom Transfer Radical Addition *via* Oxidative and Reductive Quenching of Photocatalysts.
 344*Journal of the American Chemical Society* **134**, 8875–8884 (2012).

34536. Jiang, H., Cheng, Y., Zhang, Y., Yu, S. Sulfonation and Trifluoromethylation of Enol Acetates
 346with Sulfonyl Chlorides Using Visible-Light Photoredox Catalysis. *European Journal of Organic*
 347*Chemistry* **24**, 5485–5492 (2013).

34837. Liu, X., Cong, T., Liu, P., Sun, P. Visible light-promoted synthesis of 4-
 349(sulfonylmethyl)isoquinoline-1,3(2*H*,4*H*)-diones *via* a tandem radical cyclization and
 350sulfonylation reaction. *Organic & Biomolecular Chemistry* **14**, 9416–9422 (2016).

35138. Pagire, S. K., Paria, S., Reiser, O. Synthesis of β -Hydroxysulfones from Sulfonyl Chlorides and
 352Alkenes Utilizing Visible Light Photocatalytic Sequences. *Organic Letters* **18**, 2106–2109 (2016).

35339. Alkan-Zambada, M., Hu, X. Cu-Catalyzed Photoredox Chlorosulfonation of Alkenes and
 354Alkynes. *The Journal of Organic Chemistry* **84**, 4525–4533 (2019).

35540. Luo, Q., Mao, R., Zhu, Y., Wang, Y. Photoredox-Catalyzed Generation of Sulfamyl Radicals:
 356Sulfonamidation of Enol Silyl Ether with Chlorosulfonamide. *The Journal of Organic Chemistry*
 357**84**, 13897–13907 (2019).

35841. Laudadio, G.; Barmpoutsis, E.; Schotten, C.; Struik, L.; Govaerts, S.; Browne, D. L.; Noël, T.
 359Sulfonamide Synthesis through Electrochemical Oxidative Coupling of Amines and Thiols.
 360*Journal of the American Chemical Society* **141**, 5664–5668 (2019).

36142. Hell, S. M., Meyer, C. F., Laudadio, G., Misale, A., Willis, M. C., Noel, T., Trabanco, A. A.,
 362Gouverneur, V. *Journal of the American Chemical Society* **142**, 720–725 (2020).

36343. Ignat'ev, N., Kucherina, A., Sartori, P. Comparative Electrochemical Fluorination of
 364Ethanesulfonyl Chloride and Fluoride. *Acta Chemica Scandinavica* **53**, 1110–1116 (1999).

36544. Chatgililoglu, C., Griller, D., Rossini, S. Amino- and Alkoxysulfonyl Radicals. *The Journal of*
 366*Organic Chemistry* **54**, 2734–2737 (1989).

36745. Hell, S. M.; Meyer, C. F.; Misale, A.; Sap, J. B. I.; Christensen, K. K.; Willis, M. C.; Trabanco, A.
 368A.; Gouverneur, V. Hydrosulfonylation of Alkenes with Sulfonyl Chlorides under Visible Light
 369Activation. *Angewandte Chemie International Edition* <https://doi.org/10.1002/anie.202004070>
 370(2020).